Searched for
PRANAV AMIN
Alembic Pharma Q2 Results: Net profit rises 12% to Rs 153 crore, revenue up 3%Alembic Pharma reported a 12% YoY rise in Q2FY25 net profit to Rs 153 crore, driven by strong domestic and US market sales. Revenues grew 3...- Alembic Pharma plans to launch 25 drugs in US generics segment this fiscalThe Vadodara-based drug maker, which has been around for over a century, is a late entrant in the US market. It has more than made up for i...
- Alembic aims for US rebound with new launchesAlembic Pharmaceuticals plans to launch 20 new products in the US market in FY24, including oncology and non-oncology injectables, derma, a...
- Alembic Pharma posts Rs 121 crore net profit in Q1FY24Alembic Pharma has reported a Q1 net profit of INR 121 crore, up from a net loss of INR 66 crore YoY, led by increased sales growth across ...
- Hold Alembic Pharmaceuticals, target price Rs 660: JM FinancialJM Financial has reduced its earnings by 10% in FY24/25 adjusting for higher costs, depreciation and lower other income.
- Buy Alembic Pharmaceuticals, target price Rs 653: ICICI SecuritiesAlembic Pharmaceuticals, incorporated in the year 2010, is a Mid Cap company (having a market cap of Rs 10695.00 Crore) operating in Pharma...
- Hold Alembic Pharmaceuticals, target price Rs 730: JM FinancialAlembic Pharmaceuticals, incorporated in the year 2010, is a Mid Cap company (having a market cap of Rs 11514.67 Crore) operating in Pharma...
- Alembic Pharma net profit drops 40% to Rs 176 crore in Q3FY22"India business is going to grow, and continue to grow faster than our represented market, the initiatives we have taken in last few years ...
- Alembic Pharma buys stake in US biotech RIGImmuneThe biotech was founded by Dr. Anna Pyle and Dr. Akiko Iwasaki is focused on the development of RNA based therapies for viral diseases and ...
- Optimising costs to beat price erosion in US market: Alembic PharmaceuticalsIn an interview to ET, Pranav Amin, Managing Director of Alembic Pharmaceuticals said the management still remains bullish on the US market...
- Alembic Pharma Q3 results: Net profit rises 25% to Rs 293 croreThe company had posted a net profit of Rs 234.19 crore for the corresponding period of the previous financial year, Alembic Pharmaceuticals...
- Buy Alembic Pharmaceuticals, price target Rs 720: Jayesh BhanushaliThe analyst suggested a stoploss at Rs 640.
- Alembic Pharma plans Rs 720-crore capex for FY19The pharma firm has filed 12 ANDAs (abbreviated new drug applications) during the March quarter, taking the total filings in FY18 to 26.
- Alembic Pharma opens Rs 300 crore anti-cancer drug unit in GujaratWith this facility, the Alembic Pharma will commence exporting oncology products to US, Middle East, North Africa, Australia and South Afri...
- Alembic Pharma looks to file 100 ANDAs in US in next 3 yearsAn ANDA contains data that provides for the review and ultimate approval of a generic drug product by the United States Food and Drug Admin...
- Alembic Pharma slips 3% as Q3 net tumblesMD Pranav Amin said: "Our base business in the US is doing well. We will continue to invest in R&D for future growth and have spent Rs 117 ...
- Ex-Ficci chief Chirayu Amin among 261 held in Gujarat liquor raidPolice seized liquor bottles worth Rs 1.70 lakh from farmhouse of Jitendra Shah, who owns the Shilchar group, with interests in power equip...
- Alembic Pharma Q2 net dips 58% to Rs 119.83 crThe consolidated total income from operations also declined to Rs 879.42 crore for the quarter under consideration as against Rs 1,018.07 c...
- Alembic Pharma sales up 34%, plans Brazil forayAlembic Pharmaceuticals has posted 34% rise in net sales in its first quarter result after being carved out of Alembic Ltd.
- Alembic signs licensing agreement with UCBAlembic today said it has signed $11 million licensing agreement with Belgium-based UCB for anti-epileptic drug Keppra.
Load More
